Myomo, a wearable medical robotics company, posted its financial results for the third quarter (3Q), which ended September 30.
Financial and operating highlights:
Revenue for 3Q 2025 was $10.1 million, up 10 percent compared with 3Q 2024.
Gross margin was 63.8 percent, compared with 75.4 percent for 3Q 2024.
Operating expenses for 3Q 2025 were $10 million, a decrease of 6 percent sequentially but an increase of 26 percent compared with 3Q 2024.
Adjusted earnings before interest taxes depreciation and amortization (EBITDA) for 3Q was $(2.7) million, compared with $(0.6) million for 3Q 2024. Year-to-date adjusted EBITDA was $(9.5) million, compared with $(5.3) million for the same period a year ago.
Cash, cash equivalents and short-term investments as of September 30 were $12.6 million. Cash used in operating activities was $1.8 million for 3Q, compared with $1.5 million used in 3Q 2024.
“We expect full-year 2025 revenue within our previous guidance range of $40 million to $42 million, which represents an increase of more than 23 percent versus 2024,” said Paul R. Gudonis, chairman and CEO.
